HP 560
Alternative Names: HP-560Latest Information Update: 20 Jun 2024
At a glance
- Originator Hinova pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Multiple myeloma; Myelofibrosis; Triple negative breast cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Myelofibrosis presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 12 Jul 2023 Preclinical trials in Haematological malignancies in China (unspecified route) (Hinova Pharmaceuticals, pipeline July 2023)
- 10 Jul 2023 HP 560 is available for licensing as of 10 Jul 2023 (https://www.hinovapharma.com/en/shangwuhezuo.html)